Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Neoleukin Therapeutics Inc (NLTX)
NASDAQ:NLTX
reports
Neoleukin Therapeutics (NLTX) Stock Price & Analysis
405 Followers
NLTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.38 - $3.84
Previous Close$0.6
Volume20.32K
Average Volume (3M)288.84K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$106.88M
Total Debt (Recent Filing)$12.07M
Price to Earnings (P/E)-0.5
Beta1.34
Next EarningsMar 16, 2023
EPS Estimate-$0.21
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price Target$1.30
EPS (TTM)-1.16
Shares Outstanding42,594,602
R-Squared0.05
Standard Deviation0.28
10 Day Avg. Volume106,324
30 Day Avg. Volume288,836
Price to Book (P/B)0.23
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-0.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside116.70% Upside
Rating ConsensusHold
Alpha-0.02
Number of Analyst Covering5
Neoleukin Therapeutics News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NLTX FAQ
What was Neoleukin Therapeutics’s price range in the past 12 months?
Neoleukin Therapeutics lowest stock price was $0.38 and its highest was $3.84 in the past 12 months.
What is Neoleukin Therapeutics’s market cap?
Currently, no data Available
When is Neoleukin Therapeutics’s upcoming earnings report date?
Neoleukin Therapeutics’s upcoming earnings report date is Mar 16, 2023 which is in 46 days.
How were Neoleukin Therapeutics’s earnings last quarter?
Neoleukin Therapeutics released its earnings results on Nov 14, 2022. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.304 by $0.064.
Is Neoleukin Therapeutics overvalued?
According to Wall Street analysts Neoleukin Therapeutics’s price is currently Undervalued.
Does Neoleukin Therapeutics pay dividends?
Neoleukin Therapeutics does not currently pay dividends.
What is Neoleukin Therapeutics’s EPS estimate?
Neoleukin Therapeutics’s EPS estimate is -$0.21.
How many shares outstanding does Neoleukin Therapeutics have?
Neoleukin Therapeutics has 42,594,600 shares outstanding.
What happened to Neoleukin Therapeutics’s price movement after its last earnings report?
Neoleukin Therapeutics reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.304. Following the earnings report the stock price went down -20.755%.
Which hedge fund is a major shareholder of Neoleukin Therapeutics?
Among the largest hedge funds holding Neoleukin Therapeutics’s share is Royce & Associates LLC. It holds Neoleukin Therapeutics’s shares valued at 93K.
---
Neoleukin Therapeutics Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.30
$1.30
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 7.4%
Last 30 Days ▼ 7.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.33%
12-Months-Change
Fundamentals
Return on Equity
-45.51%
Trailing 12-Months
Asset Growth
-28.05%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Neoleukin Therapeutics Inc
Neoleukin Therapeutics, Inc. is a biopharmaceutical company, which engages in the design of de novo protein therapeutics to address significant unmet medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.
---
Tonix Pharma
―
Verici Dx Plc
―
Elevation Oncology
―
RegeneRx Biopharmaceuticals
―
bioAffinity Technologies, Inc.
―
---